Which manufacturer produces niraparibabiraterone tablets?

Niraparib Abiraterone Tablets (Akeega) is an innovative targeted drug produced by the global pharmaceutical giant Johnson & Johnson. The drug combines two key ingredients: niraparib and abiraterone, and is used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who carry germline and/or somatic BRCA gene mutations.

Johnson & Johnson is a world-renowned multinational pharmaceutical company. With its leadership in drug research and development and innovative treatments, Johnson & Johnson has been committed to providing patients with more precise and personalized treatment options. The company's Janssen Pharmaceuticals division is responsible for the development and commercialization of this type of innovative drugs, and Akeega is one of its important breakthroughs in the field of cancer treatment.

The approval of niraparib and abiraterone tablets is an important development for Johnson & Johnson in the treatment of prostate cancer, especially in the treatment of metastatic castration-resistant prostate cancer (mCRPC), a refractory disease. Different from traditional treatment methods, niraparib and abiraterone tablets can inhibit the growth of cancer cells while reducing damage to normal cells and improving the patient's quality of life and survival by combining two targeted drugs, niraparib and abiraterone.

In China, Johnson & Johnson announced that its niraparib abiraterone tablets (Akeega) have been approved by the National Medical Products Administration (NMPA) and become a new generation of targeted drugs for the treatment of prostate cancer. This approval allows Chinese patients to enjoy the benefits of this innovative drug earlier, especially for those patients carrying BRCA gene mutations. Niraparib and Abiraterone Tablets provide a more effective and safer treatment option.

Reference materials:https://www.drugs.com/akeega.html